By Barbara Stephenson Posted April 18, 2020 InMelanoma2020-04-182021-03-03https://cofactorgenomics.com/wp-content/uploads/2016/10/cofactor_logo_dark.pngCofactor Genomicshttps://cofactorgenomics.com/wp-content/uploads/2016/10/cofactor_logo_dark.png200px200px MelanomaRecent PostsCofactor Genomics’ Immunotherapy Predictive Diagnostic, OncoPrism, Completes Validation and Moves Into Clinical Use in Head and Neck Cancer PatientsMultidimensional biomarker predicts disease controlCofactor Quickly Moving Immunotherapy Predictive Test to Market With Data From Intermountain SpinoutCulmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial